Phase 3 N=17 Abuse Liability of Suboxone Versus Subutex
Opioid-related Disorders
Primary: Drug's Breakpoint — 1200; 10; 1100; 1200 number of clicks on a mouse
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=170 A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
Gaucher Disease
Primary: PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAP — 80.4; 83.1 percentage of participants
Phase 3 N=677 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
Systemic Lupus Erythematosus
Primary: Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase. — 40.1; 53.8 Percentage of…
Phase 3 N=1,105 Apnea Positive Pressure Long-Term Efficacy Study
Lung Diseases · Sleep Apnea Syndromes · Sleep
Primary: Effect of CPAP on Neurocognitive Function: E/F Function- SWMT-OMD — 0.035; -0.074; 0.072; 0.018 score on a scale — p=0.0074
Phase 3 N=125 A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.
Anemia
Primary: Mean Change in Hb Concentration g/dL Between Baseline and the Efficacy Evaluation Period — 1.75 g/dL
Phase 3 N=668 Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis — 94.3; 93.0 percentage of participants — p=0.5
Phase 3 N=250 Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
Japanese Encephalitis
Primary: Number of Participants With Solicited Injection Site Reactions and Systemic Events Following a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric…
Phase 3 N=42 Expiratory Muscle Training for Persons With Neurodegenerative Disease
Parkinson's Disease · Multiple Sclerosis
Primary: Maximum Expiratory Pressure (MEP) — 78.6; 75.56; 99.00; 99.38 cm H2O — p=0.899
Phase 3 N=309 Add-on to Micamlo BP Trial
Hypertension
Primary: Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period. — -8.4; -4.5 mmHg — p=<0.0001
Phase 3 N=647 Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination) — -0.32; -1.23; -1.06; -1.72 percentage of glycosylated hemoglobin — p=< 0.0001
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Phase 3 N=11 A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 100; 18.2 Percentage of participants
Phase 3 N=62 Improving the Understanding of the Response to Vitamin D Supplementation
Vitamin D Deficiency
Primary: Change in Serum 25-hydroxy Vitamin D3 — 6.0; -0.8; 10.4; 0.3 ng/ml
Phase 3 N=165 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
Peripheral Spondyloarthritis
Primary: Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12 — 39.3; 19.8; 60.7; 80.2 percentage of participants — p=0.006
Phase 3 N=181 Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
Epilepsy
Primary: Number of Participants With Treatment-emergent Serious Adverse Event (SAE) and Adverse Event (AE) — 48; 173 Participants